JAK2 V617F Inhibitors
1 drugsAbout JAK2 V617F
JAK2 V617F is a mutated form of the Janus kinase 2 (JAK2) protein, a tyrosine kinase crucial for hematopoiesis. The V617F mutation leads to constitutive activation of the JAK-STAT signaling pathway, driving uncontrolled cell proliferation.
The direct link between the JAK2 V617F mutation and disease pathogenesis makes it a compelling therapeutic target in myeloproliferative neoplasms. There is currently no genetic evidence data available for this specific target.
JAK2 V617F is targeted by one FDA-approved drug, OJJAARA (GSK), a small molecule with two indications. GSK is the only company with an approved drug for this target.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Neoplasms with only 1 trials.
Top JAK2 V617F Drugs
GSK is the only company with an approved drug targeting JAK2 V617F.
The market is highly concentrated, suggesting high barriers to entry or limited innovation.
JAK2 V617F Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets JAK2 V617F, using small molecule modality.
Exploring alternative modalities like antibodies or PROTACs could provide a competitive advantage.
JAK2 V617F Clinical Trials 17 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 5 | 1 | 0 | 4 | 100% |
| Phase 2 | 7 | 2 | 1 | 4 | 67% |
| Phase 3 | 4 | 3 | 1 | 0 | 75% |
| Phase 4 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
JAK2 V617F Drug Approval Timeline (2023 - 2023)
The first and only drug, OJJAARA, was approved in 2023.
Recent approval suggests potential for further drug development and market growth.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 16 clinical trials targeting JAK2 V617F.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities